Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Phase II trial of hexamethylmelamine in ovarian carcinoma resistant to alkylating agents.

× No keyword cloud information.

7 in total

1. Superior efficacy of trimelamol to hexamethylmelamine in human ovarian cancer xenografts.

Authors: E Boven; M M Nauta; H M Schlüper; C A Erkelens; H M Pinedo
Journal: Cancer Chemother Pharmacol Date: 1986 Impact factor: 3.333

Review 2. Developing new drugs for ovarian cancer: a challenging task in a changing reality.

Authors: R M Canetta; S K Carter
Journal: J Cancer Res Clin Oncol Date: 1984 Impact factor: 4.553

Review 3. Altretamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy.

Authors: C R Lee; D Faulds
Journal: Drugs Date: 1995-06 Impact factor: 9.546

Review 4. N-methyl antitumour agents. A distinct class of anticancer drugs?

Authors: D Newell; A Gescher; S Harland; D Ross; C Rutty
Journal: Cancer Chemother Pharmacol Date: 1987 Impact factor: 3.333

5. Distribution, metabolism, and irreversible binding of hexamethylmelamine in mice bearing ovarian carcinoma.

Authors: E Garattini; T Colombo; M G Donelli; P Catalani; M Bianchi; M D'Incalci; C Pantarotto
Journal: Cancer Chemother Pharmacol Date: 1983 Impact factor: 3.333

6. Time dependence of the in vitro cytotoxicity of hexamethylmelamine and its metabolites.

Authors: M D'Incalci; E Erba; G Balconi; L Morasca; S Garattini
Journal: Br J Cancer Date: 1980-04 Impact factor: 7.640

7. Pentamethylmelamine (PMM): Phase I clinical and pharmacokinetic studies.

Authors: J R Muindi; D R Newell; I E Smith; K R Harrap
Journal: Br J Cancer Date: 1983-01 Impact factor: 7.640

7 in total